Major differences in organization and availability of health care and medicines for HIV/TB coinfected patients across Europe
Open Access
- 11 May 2015
- journal article
- research article
- Published by Wiley in HIV Medicine
- Vol. 16 (9) , 544-552
Abstract
Objectives: The aim of the study was to investigate the organization and delivery of HIV and tuberculosis (TB) health care and to analyse potential differences between treatment centres in Eastern (EE) and Western Europe (WE).Methods: Thirty‐eight European HIV and TB treatment centres participating in the TB:HIV study within EuroCoord completed a survey on health care management for coinfected patients in 2013 (EE: 17 respondents; WE:21; 76% of all TB:HIV centres). Descriptive statistics were obtained for regional comparisons. The reported data on health care strategies were compared with actual clinical practice at patient level via data derived from the TB:HIV study.Results: Respondent centres in EE comprised: Belarus (n = 3), Estonia (1), Georgia (1), Latvia (1), Lithuania (1), Poland (4), Romania (1), the Russian Federation (4) and Ukraine (1); those in WE comprised: Belgium (1), Denmark (1), France (1), Italy (7), Spain (2), Switzerland (1) and UK (8). Compared with WE, treatment of HIV and TB in EE are less often located at the same site (47% in EE versus 100% in WE; P < 0.001) and less often provided by the same doctors (41% versus 90%, respectively; P = 0.002), whereas regular screening of HIV‐infected patients for TB (80% versus 40%, respectively; P = 0.037) and directly observed treatment (88% versus 20%, respectively; P < 0.001) were more common in EE. The reported availability of rifabutin and second‐ and third‐line anti‐TB drugs was lower, and opioid substitution therapy (OST) was available at fewer centres in EE compared with WE (53% versus 100%, respectively; P < 0.001).Conclusions: Major differences exist between EE and WE in relation to the organization and delivery of health care for HIV/TB‐coinfected patients and the availability of anti‐TB drugs and OST. Significant discrepancies between reported and actual clinical practices were found in EE.Keywords
Funding Information
- Directorate-General for Research and Innovation (FP7/2007-2013)
- Det Frie Forskningsråd
- Research Council, Copenhagen University Hospital, Rigshospitalet
This publication has 21 references indexed in Scilit:
- The HIV Epidemic in Eastern Europe and Central AsiaCurrent HIV/AIDS Reports, 2014
- Drug-resistant TB can be containedNature, 2014
- The case for indicator condition‐guided HIV screeningHIV Medicine, 2013
- Health care index score and risk of death following tuberculosis diagnosis in HIV-positive patientsThe International Journal of Tuberculosis and Lung Disease, 2013
- Multidrug-resistant tuberculosis in Belarus: the size of the problem and associated risk factorsBulletin of the World Health Organization, 2012
- Mortality from HIV and TB coinfections is higher in Eastern Europe than in Western Europe and ArgentinaAIDS, 2009
- Treating Multidrug‐Resistant Tuberculosis in Tomsk, RussiaAnnals of the New York Academy of Sciences, 2008
- Integration and co-location of HIV/AIDS, tuberculosis and drug treatment servicesInternational Journal of Drug Policy, 2007
- Health service providers' perceptions of barriers to tuberculosis care in RussiaHealth Policy and Planning, 2006
- Predictors of adherence to tuberculosis treatment in a supervised therapy programme for prisoners before and after release. Study Group of Adherence to Tuberculosis Treatment of PrisonersEuropean Respiratory Journal, 1998